GlassScriptPhysician profile
Luis Alberto Berrios
NPI 1659308427
$7,712.46
in general payments reported to CMS, 2019-2025
36 companies · $992 in 2025
The $992 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,813 · 2022: $2,087 · 2023: $1,569 · 2024: $1,251 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,195.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,053.14 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $918.25 | 2021-2025 | |
| Novo Nordisk INC | $875.23 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $499.38 | 2021-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $484.26 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $436.68 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $313.28 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $191.96 | 2021 | |
| Amarin Pharma, INC. | $177.84 | 2021-2022 | |
| Dexcom, INC. | $165.68 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $135.27 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Horizon Therapeutics Plc | $131.55 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.57 | 2021-2025 | |
| Glaxosmithkline, LLC. | $116.02 | 2021-2025 | Trelegy Ellipta, Shingrix |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $115.62 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.34 | 2021-2023 | Jardiance |
| Esperion Therapeutics, INC. | $71.96 | 2021-2025 | Nexletol |
| Daiichi Sankyo INC. | $61.27 | 2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $57.55 | 2023-2025 | Rexulti |
| Eisai INC. | $54.52 | 2021 | |
| Currax Pharmaceuticals LLC | $51.32 | 2021-2022 | |
| Astellas Pharma US INC | $50.45 | 2021-2023 | Veozah |
| Abbott Laboratories | $47.26 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $38.27 | 2021-2022 | |
| Exact Sciences Corporation | $37.29 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $37.28 | 2024 | Korlym |
| Antares Pharma, INC. | $29.72 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Tolmar, INC. | $28.52 | 2023-2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $22.65 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $22.64 | 2021 | |
| Zimmer Biomet Holdings, INC. | $22.30 | 2024 | |
| Boston Scientific Corporation | $21.90 | 2025 | General - Therapies |
| Teva Pharmaceuticals USA, INC. | $19.64 | 2021 | |
| Sumitomo Pharma America, INC. | $16.12 | 2023 | Gemtesa |
| Clarus Therapeutics INC. | $14.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Berrios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.